FLT3抑制剂治疗急性髓系白血病:十个常见问题
约三分之一的急性髓系白血病(AML)患者存在FLT3基因突变,其中FLT3-ITD突变者复发风险高、治愈率低。已开发出多种FLT3酪氨酸激酶抑制剂,分为第一代多激酶抑制剂(如索拉非尼、来他替尼、米哚妥林)和下一代抑制剂(如奎扎替尼、克雷诺拉尼、吉列替尼)。本综述以问答形式讨论了白血病专家在AML中使用FLT3抑制剂时面临的主要问题。
要点
- AML中约三分之一患者存在FLT3突变,FLT3-ITD提示高复发风险和低治愈率。
- FLT3抑制剂分为第一代多激酶抑制剂和下一代高选择性抑制剂。
- FLT3抑制剂在初治、复发难治及维持治疗等多种场景中进行了临床试验。
核心结论
- FLT3抑制剂在AML治疗中应用广泛,需根据抑制效力、特异性和临床场景选择。
研究设计与样本
- 实用问答式综述,讨论白血病专家在AML中使用FLT3抑制剂的主要问题。
主要发现
- FLT3基因在约三分之一AML患者中突变,主要为内部串联重复(FLT3-ITD)或酪氨酸激酶域点突变(FLT3-TKD)。
- FLT3-ITD患者复发风险高且治愈率低。
- 第一代FLT3抑制剂包括索拉非尼、来他替尼、米哚妥林;下一代包括奎扎替尼、克雷诺拉尼、吉列替尼。
- FLT3抑制剂已在多种临床试验中作为单药或联合化疗/低甲基化药物,用于初治、复发难治及巩固化疗或异基因干细胞移植后维持治疗。
临床怎么用
- 临床医生应了解不同FLT3抑制剂的激酶抑制特性、药代动力学和毒性特征,以个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by a point mutation mainly involving the tyrosine kinase domain (FLT3-TKD). Patients with FLT3-ITD have a high risk of relapse and low cure rates. Several FLT3 tyrosine kinase inhibitors have been developed in the last few years with variable kinase inhibitory properties, pharmacokinetics, and toxicity profiles. FLT3 inhibitors are divided into first generation multi-kinase inhibitors (such as sorafenib, lestaurtinib, midostaurin) and next generation inhibitors (such as quizartinib, crenolanib, gilteritinib) based on their potency and specificity of FLT3 inhibition. These diverse FLT3 inhibitors have been evaluated in myriad clinical trials as monotherapy or in combination with conventional chemotherapy or hypomethylating agents and in various settings, including front-line, relapsed or refractory disease, and maintenance therapy after consolidation chemotherapy or allogeneic stem cell transplantation. In this practical question-and-answer-based review, the main issues faced by the leukemia specialists on the use of FLT3 inhibitors in AML are addressed.
引用
- Antar AI, Otrock ZK, Jabbour E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020. PMID: 31919472. doi:10.1038/s41375-019-0694-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。